| Similar Articles |
|---|
 |
The Motley Fool
June 23, 2011
Brian Orelli |
In Addition, Our Drug Actually Rocks Pfizer and Bristol get good data on Eliquis.   |
The Motley Fool
November 30, 2011
Brian Orelli |
Drugmakers Bleeding Out That's not what blood thinners are supposed to do. |
The Motley Fool
July 5, 2011
Brian Orelli |
Drug Approved, But No Fireworks Yet The second FDA approval for Bayer and Johnson & Johnson's Xarelto is more important. |
The Motley Fool
April 6, 2011
Brian Orelli |
$1 Billion in Drug Sales Bleeds Out Don't feel too bad for Bayer and J&J though. |
The Motley Fool
September 7, 2011
Brian Orelli |
J&J and Bayer Head in Front of the Firing Squad An expanded indication for Xarelto seems unlikely. |
The Motley Fool
September 9, 2011
Brian Orelli |
Firing Squad, It Was Not J&J and Bayer get through their advisory panel with minimal problems. |
The Motley Fool
June 11, 2010
Brian Orelli |
Pfizer and Bristol Coagulate Against Clots Let's see how apixaban does against warfarin before we break out the "blockbuster" stamp. |
The Motley Fool
August 24, 2011
Alexander Crawford |
Pfizer & Bristol-Myers to Release Highly Anticipated Data on Bloodthinner Hopeful How big could this market be? |
The Motley Fool
November 16, 2010
Brian Orelli |
Well, That Just Stinks Glaxo's Lovaza doesn't fix heart rhythm problems. |
The Motley Fool
November 30, 2011
Brian Orelli |
3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming. |
The Motley Fool
November 15, 2010
Brian Orelli |
A Mega-Blockbuster Showdown Boehringer Ingelheim's Pradaxa was recently approved to treat patients with an erratic heartbeat, and Bayer and Johnson & Johnson have a second compound, Xarelto, that isn't far behind. |
The Motley Fool
November 22, 2010
Brian Orelli |
Pfizer's Mixed Bag Pfizer had a mixed bag of clinical trial results at the end of last week. And probably the company would have rather seen the results flip-flopped. |
The Motley Fool
September 8, 2011
Arlene Weintraub |
Bristol-Pfizer Team on Alert as FDA Reviews Stroke-Prevention Drug From Rivals J&J and Bayer Who will come out ahead? |
American Family Physician
July 15, 2002 |
Atrial Fibrillation What is atrial fibrillation?... Who gets atrial fibrillation and why?... How can my doctor and I tell that I have atrial fibrillation?... How is atrial fibrillation treated?... What can I expect in the future? |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
August 3, 2011
Brian Orelli |
Ignore Pfizer's Financials for Now It's the pipeline that matters. |
The Motley Fool
September 30, 2011
David Williamson |
This Week in Health Care Pharma news about Pfizer, AstraZeneca, and the multibillion-dollar battle to replace the maligned blood-thinner warfarin. |
The Motley Fool
November 7, 2011
David Williamson |
Health-Care News You Can't Afford to Miss Highlighting the day's health-care stories: FDA approval for Johnson & Johnson... Inhibitex kept its streak of double-digit gains alive with another 14% surge today... 13% plunge for Optimer Pharmaceuticals... |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Acute Coronary Syndrome A new class of anticoagulants is competing to dethrone difficult-to-manage warfarin, long the sole option in the prevention of stroke and other bleeding complications in the 2.5 million US patients with atrial fibrillation. |
The Motley Fool
July 29, 2011
Brian Orelli |
Bristol-Myers Grows in the Wrong Places Bristol-Myers has a solid quarter, but Plavix and currency movements aren't important. |
American Family Physician
July 15, 2002
Dana E. King |
Acute Management of Atrial Fibrillation: Part II. Prevention of Thromboembolic Complications Family physicians should be familiar with the acute management of atrial fibrillation and the initiation of chronic therapy for this common arrhythmia. Part II of this two-part article focuses on the prevention of thromboembolic complications using anticoagulation. |
The Motley Fool
July 2, 2009
Robert Steyer |
At Last, a Heartening Drug Approval French drug giant sanofi-aventis gets FDA approval for a drug to treat an erratic heartbeat. |
The Motley Fool
April 9, 2009
Brian Orelli |
Cash: The Cure for Smaller Drugmakers For $60 million and a credit line of an additional $100 million, Merck licenses the rights to the oral formulation of vernakalant, Cardiome's atrial fibrillation treatment. |
American Family Physician
June 15, 2005
Mark H. Ebell |
Decision-Making Tool for Treating Patients with Nonvalvular Atrial Fibrillation What is the risk of stroke in a patient with nonvalvular atrial fibrillation, and should that patient be given warfarin (Coumadin) or aspirin? |
The Motley Fool
August 17, 2007
Brian Orelli |
FDA's Rigor May Boost Sales The FDA is updating labeling of certain blood-thinning drugs, indicating that patients may want to obtain a genetic test prior to taking the medication. This move may lead to increased testing, and hopefully increased prescriptions. |
The Motley Fool
May 29, 2009
Brian Orelli |
Delayed, Reason Unknown As long as Bayer and Johnson & Johnson can answer the FDA's questions relatively quickly, it shouldn't affect the companies too much. |
American Family Physician
July 15, 2002
Dana E. King |
Acute Management of Atrial Fibrillation: Part I. Rate and Rhythm Control Atrial fibrillation is the arrhythmia most commonly encountered in family practice. Initial treatment is directed at controlling the ventricular rate. Medical or electrical cardioversion to restore sinus rhythm is the next step in patients who remain in atrial fibrillation. |
The Motley Fool
November 27, 2007
Brian Lawler |
Cardiome Makes Them Wait Cardiome Pharma announces a delay in the release of data on an oral version of its lead heart drug. Investors, take note. |
The Motley Fool
August 28, 2007
Andrew R. Vaino |
Cardiome's Hearty Outlook If the FDA renders a favorable decision on an anti-fibrillation drug, Cardiome's heart may well skip a beat. As with any investment based on FDA approval, of course, there is substantial risk involved. |
The Motley Fool
March 19, 2009
Brian Orelli |
One Down, One to Go Sanofi-aventis slides past an FDA panel and hopes for more good news today |
The Motley Fool
April 28, 2011
Brian Orelli |
1 Year to P-Day, Bristol-Myers Squibb Looks Just Fine New drugs should help cushion the fall from the loss of Plavix. |
The Motley Fool
January 12, 2012
Brian Orelli |
What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see. |
The Motley Fool
August 12, 2011
David Williamson |
What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter? |
American Family Physician
June 15, 2002
A. Kesh Hebbar |
Management of Common Arrhythmias: Part I. Supraventricular Arrhythmias Family physicians frequently encounter patients with symptoms that could be related to cardiac arrhythmias, most commonly atrial fibrillation or supraventricular tachycardias. |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note. |
The Motley Fool
February 17, 2006
Stephen D. Simpson |
AtriCure Sends Investors' Hearts Aflutter AtriCure addresses a real market, but faces a typically rocky road. But executing on a big opportunity can mean ample rewards for patient investors. |
| AskMen.com |
Living With A Heart Condition Actor and comedian Kevin Nealon is proof that older men can live (and thrive) with a heart condition |
